By Fineline Cube 
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that JUVÉDERM VOLBELLA WITH LIDOCAINE has received approval from China’s National Medical Products Administration (NMPA) for the correction of infraorbital hollowing — expanding the hyaluronic acid filler’s Chinese label beyond its existing lip indication.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | New indication for an approved medical aesthetics product |
| Product | JUVÉDERM VOLBELLA WITH LIDOCAINE (hyaluronic acid dermal filler) |
| New Indication | Correction of infraorbital hollowing |
| Existing Chinese Approval | Since 2021: correction of lip structural defects — the earliest hyaluronic acid product in China approved for a lip indication |
| Approval Basis | Phase III clinical study |
| Announcement Date | 10 Sep 2026 |
| Launch Timing / Pricing | Not disclosed |
Product Profile & Mechanism of Action
- Molecule: Hyaluronic acid (HA) dermal filler with integrated lidocaine to improve injection comfort — administered by qualified healthcare professionals for soft‑tissue correction.
- Indication Expansion: Moves from lip structural defect correction into the infraorbital (under‑eye) region, one of the most technically demanding and fastest‑growing treatment areas in facial aesthetics.
- Pioneer Position: As the first HA product approved in China for a lip indication (2021), VOLBELLA established an early‑mover regulatory footprint that this new approval further extends.
- Evidence Base: Label expansion supported by a dedicated Phase III clinical study with a 12‑month follow‑up observation period.
Clinical Evidence – Phase III Study
| Endpoint | Result (JUVÉDERM VOLBELLA) | Time Point | Notes |
|---|---|---|---|
| AIHS Improvement ≥1 Grade | 94.6 % of subjects | 3 months post‑treatment | Allergan Infraorbital Hollowing Scale |
| GAIS Responder Rate (Investigator‑Assessed) | 99.1 % | Study assessment | Global Aesthetic Improvement Scale |
| GAIS Responder Rate (Subject‑Assessed) | 95.6 % | Study assessment | Global Aesthetic Improvement Scale |
| Durability | Treatment effect remained stable | 12‑month follow‑up | Favorable safety profile throughout observation period |
In the pivotal Phase III study, 94.6 % of subjects in the JUVÉDERM VOLBELLA treatment group achieved an improvement of ≥1 grade on the Allergan Infraorbital Hollowing Scale (AIHS) at 3 months, with GAIS responder rates of 99.1 % (investigator‑assessed) and 95.6 % (subject‑assessed). Over the 12‑month follow‑up, the treatment effect remained stable with a favorable safety profile. Sample size and study site details were not disclosed.
Market Impact & Outlook
- China Aesthetics Growth Driver: China’s medical aesthetics market ranks among the world’s largest and fastest‑evolving, with rising consumer demand for under‑eye rejuvenation — a treatment area historically constrained by the limited availability of NMPA‑approved products.
- Regulatory Moat: As the earliest HA filler approved for a lip indication in China, and now with an infraorbital hollowing approval backed by Phase III data, VOLBELLA strengthens Allergan Aesthetics’ differentiated, compliance‑first positioning in a market where approved devices command a premium over unregulated alternatives.
- Portfolio Expansion: The new indication broadens the JUVÉDERM franchise in China, supporting cross‑treatment‑area utilization among existing injectors and clinics.
- Durability as a Selling Point: The 12‑month stable effect with favorable safety profile provides a compelling long‑term value proposition for both practitioners and consumers; commercialization timing and pricing were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the launch, adoption and commercial performance of JUVÉDERM VOLBELLA WITH LIDOCAINE in China. Actual results may differ materially due to risks including market adoption, competitive dynamics, regulatory and pricing environment, and consumer demand in the medical aesthetics sector. Launch timing and pricing were not disclosed.-Fineline Info & Tech